Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Guardian Pharmacy Services Inc (NYSE: GRDN) was $29.5 for the day, down -2.09% from the previous closing price of $30.13. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 0.55 million shares were traded. GRDN stock price reached its highest trading level at $31.25 during the session, while it also had its lowest trading level at $28.56.
Ratios:
Our analysis of GRDN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 51.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.40. For the most recent quarter (mrq), Quick Ratio is recorded 0.93 and its Current Ratio is at 1.22. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on October 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $30.
On October 21, 2024, Truist started tracking the stock assigning a Buy rating and target price of $22.
On October 21, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $21.Raymond James initiated its Outperform rating on October 21, 2024, with a $21 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 03 ’25 when COSLER STEVEN D bought 3,370 shares for $29.61 per share. The transaction valued at 99,786 led to the insider holds 24,984 shares of the business.
Cardinal Equity Fund, L.P. sold 270,958 shares of GRDN for $5,462,513 on May 27 ’25. The Member of 10% owner group now owns 200,099 shares after completing the transaction at $20.16 per share. On May 28 ’25, another insider, Cardinal Equity Fund, L.P., who serves as the Member of 10% owner group of the company, sold 50,305 shares for $20.16 each. As a result, the insider received 1,014,149 and left with 149,794 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GRDN now has a Market Capitalization of 1867974272 and an Enterprise Value of 1882520704. As of this moment, Guardian’s Price-to-Earnings (P/E) ratio for their current fiscal year is 46.35, and their Forward P/E ratio for the next fiscal year is 27.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.34 while its Price-to-Book (P/B) ratio in mrq is 10.17. Its current Enterprise Value per Revenue stands at 1.355 whereas that against EBITDA is 22.396.
Stock Price History:
The Beta on a monthly basis for GRDN is 0.97, which has changed by 0.456259 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, GRDN has reached a high of $37.43, while it has fallen to a 52-week low of $17.78. The 50-Day Moving Average of the stock is -1.36%, while the 200-Day Moving Average is calculated to be 17.01%.
Shares Statistics:
GRDN traded an average of 310.01K shares per day over the past three months and 261560 shares per day over the past ten days. A total of 36.25M shares are outstanding, with a floating share count of 22.49M. Insiders hold about 64.49% of the company’s shares, while institutions hold 31.27% stake in the company. Shares short for GRDN as of 1767139200 were 1158683 with a Short Ratio of 3.74, compared to 1764288000 on 1285458. Therefore, it implies a Short% of Shares Outstanding of 1158683 and a Short% of Float of 4.44.
Earnings Estimates
The performance of Guardian Pharmacy Services Inc (GRDN) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.24, with high estimates of $0.27 and low estimates of $0.23.
Analysts are recommending an EPS of between $1.01 and $0.96 for the fiscal current year, implying an average EPS of $0.98. EPS for the following year is $1.09, with 4.0 analysts recommending between $1.14 and $1.03.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $392.72M to a low estimate of $387.61M. As of. The current estimate, Guardian Pharmacy Services Inc’s year-ago sales were $338.57MFor the next quarter, 4 analysts are estimating revenue of $339.06M. There is a high estimate of $345.3M for the next quarter, whereas the lowest estimate is $331.92M.
A total of 4 analysts have provided revenue estimates for GRDN’s current fiscal year. The highest revenue estimate was $1.44B, while the lowest revenue estimate was $1.44B, resulting in an average revenue estimate of $1.44B. In the same quarter a year ago, actual revenue was $1.23BBased on 4 analysts’ estimates, the company’s revenue will be $1.44B in the next fiscal year. The high estimate is $1.45B and the low estimate is $1.42B.
